

## Disclosures

### Personal Commercial (13)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Ache	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
Adium	Speaker's Bureau	Modest (< \$5,000)	Prevention
AMGEN	Consultant Fees/Honoraria	Significant (>= \$5,000)	Prevention
Biolab	Speaker's Bureau	Modest (< \$5,000)	Prevention
Daichii-Sankyo	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
Eli Lilly and Company	Speaker's Bureau	Modest (< \$5,000)	Prevention
Esperion	Research/Research Grants	Modest (< \$5,000)	Prevention
Ionis	Research/Research Grants	Modest (< \$5,000)	Prevention
Merck & Co., Inc.	Research/Research Grants	Modest (< \$5,000)	Prevention
Novartis Corporation	Consultant Fees/Honoraria	Significant (>= \$5,000)	Prevention Vascular Medicine
Novo-Nordisk	Consultant Fees/Honoraria	Significant (>= \$5,000)	Prevention
Sanofi/Regeneron	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
Ultragenyx	Speaker's Bureau	Modest (< \$5,000)	Prevention

### Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

### Personal Organizational or Other Non-Commercial (6)

Non-Commercial Entity Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Amgen	Research/Research Grants ‡ Hauser	Modest (< \$5,000)	Prevention
Atherosclerosis	Officer, Director, Trustee, or other Fiduciary Role	None (\$0)	Prevention
European Journal of Preventive Cardiology	Other - Associate Editor	None (\$0)	Prevention
International Atherosclerosis Society	Officer, Director, Trustee, or other Fiduciary Role	None (\$0)	Prevention
Journal of Clinical Lipidology	Officer, Director, Trustee, or other Fiduciary Role	None (\$0)	Prevention
World Heart Federation	Officer, Director, Trustee, or other Fiduciary Role	None (\$0)	Prevention

### Clinical Trial Enroller (6)

Trial Name	Trial Sponsor	Trial Funding Source
Ocean study	Amgen	
HAUSER	Amgen	
Acclaim Lp(a)	Eli Lilly and Company	
ORION-16	Novartis Corporation	
HORIZON	Novartis Corporation	Novartis Corporation
ODYSSEY KIDS	SANOFI	

### Institutional Financial Decision-Making Role (0)

No disclosures on record

## Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

## Agreement

---

### **Certified Education Attestation** | Signed on 3/5/2026

*URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>*

### **Confidentiality, Disclosure and Assignment Agreement** | Signed on 3/5/2026

*URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>*

### **Embargo** | Signed on 3/5/2026

*URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>*

### **On-Going Obligation Agreement** | Signed on 3/5/2026

---

## ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.